# Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection

> **NCT07555431** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Carlos Brites** · enrollment: 146 (estimated)

## Conditions studied

- HTLV-1 Infection
- HTLV I Associated Myelopathies
- HTLV I Associated T Cell Leukemia Lymphoma
- Neuritis

## Interventions

- **COMBINATION_PRODUCT:** Combination of Dolutegravir + Tenofovir DF for treatment of HTLV-1 infection
- **DRUG:** Dolutegravir (DTG)

## Key facts

- **NCT ID:** NCT07555431
- **Lead sponsor:** Carlos Brites
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2028-05
- **Final completion:** 2028-06
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07555431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07555431, "Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT07555431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*